GlassScriptPhysician profile
Tommy Love
NPI 1689681355
$3,841.69
in general payments reported to CMS, 2019-2025
25 companies · $243 in 2025
The $243 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $806 · 2020: $568 · 2021: $514 · 2022: $715 · 2023: $459 · 2024: $536 · 2025: $243.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,238.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,237.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $742.37 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Glaxosmithkline, LLC. | $710.09 | 2019-2025 | Arexvy, Trelegy Ellipta |
| Novartis Pharmaceuticals Corporation | $410.27 | 2019-2023 | |
| Janssen Pharmaceuticals, INC | $270.91 | 2019-2022 | |
| Astellas Pharma US INC | $231.86 | 2020-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $217.00 | 2019-2024 | Jardiance, Ofev, Tradjenta |
| Pfizer INC. | $194.06 | 2019-2023 | |
| Sanofi-Aventis U.S. LLC | $147.82 | 2019-2023 | |
| Novo Nordisk INC | $126.28 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Amarin Pharma, INC. | $118.36 | 2020-2021 | |
| Abbott Laboratories | $103.55 | 2022 | |
| Abiomed | $75.91 | 2023 | Impella |
| Biogen, INC. | $68.47 | 2020-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $66.91 | 2022 | |
| Lilly USA, LLC | $60.35 | 2021-2023 | Mounjaro |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $57.47 | 2022-2025 | Gvoke Hypopen |
| Baxter Healthcare | $57.32 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $49.04 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $33.16 | 2019-2020 | |
| Paratek Pharmaceuticals, INC. | $20.86 | 2022 | |
| Horizon Therapeutics Plc | $18.54 | 2019 | |
| Esperion Therapeutics, INC. | $17.07 | 2020 | |
| Dexcom, INC. | $17.04 | 2021 | |
| Exact Sciences Corporation | $15.46 | 2025 | Cologuard Collection Kit |
| Allergan, INC. | $11.52 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tommy Love listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.